Cd34 qbend 10

Samples were stained with haematoxylin–phloxin–saffron (HPS) according to standard protocols. All tissue samples were centrally reviewed (DFB, AM). For each case, the following pathological features were searched for: diffuse or circumscribed growth pattern, microvascular proliferation, tumoral necrosis, calcification, dysmorphic ganglion cells, specific glioneuronal element, mitotic activity (/mm²). Search for immunohistochemical expression of OLIG2 (6F2, Dako®), CD34 (QBEnd10, Roche®), Neurofilament (2F11, Menarini®), Ki67 (MIB1, Dako®), FGFR3 (FGFR3, Clinisciences®) was performed. Cases presenting pathological features of microvascular proliferation and/or tumoral necrosis were classified as glioblastoma (GB), cases without microvascular proliferation and lack of tumoral necrosis were classified as low-grade glioma (LGG).

For immunocytochemistry, cytospin preparations of BMEN1 cells were analyzed by the OHSU Department of Pathology using Ventana V9 anti-Vimentin on a Vantan XT instrument according to the manufacturer standard protocol (Ventana Medical Systems, Tucson, AZ). For immunohistochemistry of meningiomas and medulloblastomas and associated meninges, 7-micron sections were prepared from formalin-fixed, paraffin-embedded tissues. Deparaffinized sections were blocked and treated with antibodies to MMP9 (EP1255Y from Novus Biologicals, Littleton, CO), Vimentin (V9 from Ventana), CD68 (KP-1 from Ventana), Collagen IV (CIV-22 from Cell Marque, Rocklin, CA), CD34 (QBEND-10 from Ventana), factor VIII (rabbit polyclonal antibody from Cell Marque), or CD61 (2F-2 from Cell Marque). MMP9 was used at 1:500 dilution and developed by hand using Vector Red alkaline phosphatase substrate (Vector Laboratories, Burlingame, CA). All other immunohistochemical stains were performed on a Ventana Benchmark XT autostainer according to protocols specifiied by the manufacturer, and developed using diaminobenzidine chromogen.